|
30 Aug 2022 |
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
|
|
29 Aug 2022 |
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
|
|
29 Aug 2022 |
ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma
|
|
27 Aug 2022 |
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
|
|
27 Aug 2022 |
Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection
|
|
25 Aug 2022 |
Zelluna Immunotherapy Announces Investment from Takeda Ventures, Inc.
|
|
25 Aug 2022 |
First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)
|
|
24 Aug 2022 |
Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME
|
|
24 Aug 2022 |
mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA
|
|
23 Aug 2022 |
VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA
|
|
23 Aug 2022 |
Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress
|
|
23 Aug 2022 |
BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington’s Disease
|
|
22 Aug 2022 |
Chugai and Noile-Immune Biotech Enter into a License Agreement for Noile-Immune’s PRIME CAR-T Technology
|
|
19 Aug 2022 |
FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
|
|
19 Aug 2022 |
Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110TM, a KIR-CAR T-cell Immunotherapy Candidate
|
|
18 Aug 2022 |
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
|
|
18 Aug 2022 |
VRG announces major milestone in chlorotoxin targeted CAR T therapy in glioblastoma
|
|
18 Aug 2022 |
Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)
|
|
18 Aug 2022 |
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
|
|
17 Aug 2022 |
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
|
|
12 Aug 2022 |
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
|
|
11 Aug 2022 |
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
|
|
10 Aug 2022 |
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
|
|
10 Aug 2022 |
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
|
|
10 Aug 2022 |
Cure Rare Disease Receives FDA Approval to Administer First-in-Human CRISPR Therapeutic
|
